Kymera Therapeutics, Inc. (NASDAQ:KYMR) disclosed that Chief Operating Officer Jeremy G. Chadwick sold 6,551 shares of the companys common stock across transactions on April 14 and 15, 2026. The aggregate proceeds from those sales amounted to approximately $589,598, with the trades executed at a weighted average price spanning $90.00 to $90.0016 per share.
Alongside the sales, Chadwick exercised options to purchase a total of 6,551 shares of Kymera common stock on the same dates. The option strike prices ranged from $30.17 to $43.50, and the exercise represented a total cost of $225,436.
Company filings indicate these dispositions and option exercises were carried out under a pre-arranged Rule 10b5-1 trading plan that Chadwick adopted on December 10, 2025. The timing of the executed trades follows a period of notable share-price appreciation: Kymera shares have risen 244% over the past year. At present, the stock is quoted at $86.14 per share, below the prices realized in the April sales.
Valuation note
Third-party analysis cited in company commentary characterizes Kymera as appearing overvalued at current levels, placing the stock on a Most Overvalued list in that analysis. The valuation assessment sits alongside the insider activity and the recent absolute price performance, creating a mixed set of signals for market participants.
Program and partnership updates
Kymera has recently received Fast Track designation from the U.S. Food and Drug Administration for KT-621, an oral STAT6 degrader being developed to treat moderate to severe eosinophilic asthma. KT-621 is presently in Phase 2b studies for both asthma and atopic dermatitis. The company plans to present data from its KT-621 atopic dermatitis trial at the American Academy of Dermatology Annual Meeting in 2026.
Separately, Kymera announced that Gilead Sciences exercised its option to license KT-200, a CDK2 degrader. That exercise triggered a $45 million payment to Kymera and will see Gilead advance KT-200 into further studies, with an investigational new drug filing anticipated in 2027.
Analyst coverage
On the equity research front, H.C. Wainwright reiterated a buy rating on Kymera and maintained a $134 price target, citing the Gilead decision as a favorable development. Stephens has increased its price target to $100, noting the companys pipeline progress and that recent execution has been consistent with previous guidance.
What investors should note
The disclosed insider sale and parallel option exercise were performed under a pre-established trading plan. The company remains active on multiple development and partnership fronts, while third-party valuation analysis flags the shares as appearing overvalued at current market levels.